managedmedically. The signs and symptomsof hyperthyroidism may not lead to the diagnosis of a TSH-secreting adenoma, as the hyperthyroidism is mild in most of the cases and it is complicated with a variety of symptoms of pituitary tumors such as headache, optical disturbances, hypogonadism and/or infertility. The diagnosis of TSH-secreting pituitary adenomas can be made only by confirming the characteristic finding of increased thyroid hormone levels with non-suppressed TSH, the so-called "inappropriate secretion of TSH (ISTSH)" where a negative feedback mechanismis not operating normally. Non-suppressed or detectable TSHis the most critical distinction to differentiate TSH-mediated hyperthyroidism from Graves' disease as Fukuda et al (3) described in this issue of Internal Medicine.
See also p 1027.
It must be emphasized that the development of the ultrasensitive TSHassay made the differential diagnosis easier (4), and the number of reported cases has increased thereafter (5). Contrary to our expectation, it turned out that long-term bromocriptine therapy was not effective for TSH-secreting adenomasbecause of incomplete suppression or reboundelevation of TSH (1, 2). At present, we have a potent alternative, "octreotide". In contrast to bromocriptine, most TSH-secreting adenomas respond to somatostatin (7) and its long-acting analogue, octreotide (1, 5, 8, 9). TSH levels returned to normal in 2/3 (8, 9) or 90% (5) and the tumor size was reduced in 1/3 (8, 9) or 45% (5) of the reviewed literature cases of TSHsecreting adenomas treated by octreotide using the typical daily dose of 100-500 jig. Tahyphylaxis was seldom reported. A varying response to octreotide may be due to the heterogenous distribution of somatostatin receptor among TSHadenomas (10) . In vitro studies have demonstrated certain numbersof somatostatin receptors with various affinities (1 1). A good correlation was reported between the uptake and TSHsuppression in TSH-secreting adenomas by octreotide scintigraphy (12) . Thus, octreotide is the most promising medical tool for a treatment of patients with TSH-secreting pituitary adenomas 
